Astria Therapeutics, Inc.
ATXS
$4.04
$0.061.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -29.32% | -82.75% | -90.23% | -71.14% | -40.62% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.00% | 64.00% | 83.33% | 79.83% | 21.31% |
| Change in Net Operating Assets | 288.27% | -431.40% | 1,510.64% | 50.35% | -191.16% |
| Cash from Operations | -18.65% | -92.52% | -79.17% | -67.97% | -57.23% |
| Capital Expenditure | -1,200.00% | -752.50% | -245.74% | 79.17% | 72.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -241.80% | -9,945.49% | -5,080.41% | -438.10% | 180.87% |
| Cash from Investing | -242.07% | -10,172.14% | -5,210.72% | -438.73% | 180.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 77.83% | 102.94% | 58.58% | 59.00% | -38.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 77.83% | 102.94% | 58.58% | 59.00% | -38.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -174.75% | -152.92% | -144.94% | -119.48% | 335.07% |